Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
NCT00676338 on ClinicalTrials.gov · last registry update 2015-04-09
Finished July 2010, after enrolling 820 people. Primary outcome, as filed: Change in HbA1c From Baseline to Week 26. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Enrollment
- 820
- Started
- 2008-11
- Primary completion
- 2010-07 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c From Baseline to Week 26
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.